# FDA 483 - Dendreon Pharmaceuticals LLC - January 09, 2015

Source: https://www.globalkeysolutions.net/records/483/dendreon-pharmaceuticals-llc/822eb493-a842-4f0e-af97-b9c9dd995417

> FDA 483 for Dendreon Pharmaceuticals LLC on January 09, 2015. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Dendreon Pharmaceuticals LLC
- Inspection Date: 2015-01-09
- Product Type: biologics
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of U.S. Manufacturing Operations in Union City, GA, a cellular therapy manufacturer, revealed two significant observations. The firm's Quality Assurance Unit failed to ensure thorough review and adequate evaluation of customer complaints, including initiating adverse events for unreleased products with low cell counts. Additionally, corrective actions implemented to prevent training investigation exception reports were found to be inadequate, with ongoing issues related to employee training records.

## Related Documents

- [483 - 2018-10-22](https://www.globalkeysolutions.net/records/483/dendreon-pharmaceuticals-llc/a4c2e9e4-ef11-46c5-89bc-9f9f39b154b3)
- [483 - 2022-04-21](https://www.globalkeysolutions.net/records/483/dendreon-pharmaceuticals-llc/25a116c3-0c75-49e3-a561-9f023a1b9016)

## Related Officers

- [Investigator](https://www.globalkeysolutions.net/people/burnell-m-henry/dece4407-3597-4a58-8756-5abf9db43bbc)

Company: https://www.globalkeysolutions.net/companies/dendreon-pharmaceuticals-llc/3de4a8e5-8e34-4212-8862-ecd5256c6ffe

Office: https://www.globalkeysolutions.net/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1